Filing Analysis
Imunon, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Key outcomes included the election of Class I directors, ratification of the independent auditor, and approval of an amendment to the 2018 Stock Incentive Plan.
📋 Key Facts
- Stockholders approved an increase of 1,000,000 shares to the 2018 Stock Incentive Plan, bringing the new aggregate limit to 1,265,004 shares.
- Mr. Frederick J. Fritz and Ms. Christine A. Pellizzari were elected as Class I directors until 2029.
- WithumSmith + Brown, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The 2025 executive compensation ('Say-on-Pay') was approved on an advisory basis.
- A quorum was established with 1,808,666 shares represented out of 3,983,342 outstanding shares.
Imunon, Inc. entered into a complex $10 million financing arrangement with Streeterville Capital, LLC involving the issuance of Series A Preferred Stock and two secured promissory notes. While the company received $10 million in cash, 50% of these proceeds are immediately restricted as collateral for the debt.
🚩 Red Flags
- High collateralization: 50% of the funding is restricted in a collateral account, limiting immediate liquidity.
- Aggressive security: The notes are secured by 'substantially all of the assets of the Company', creating significant risk of asset loss upon default.
- Restrictive redemption: Investor can redeem principal of Note A-1 monthly starting in six months, and can redeem additional amounts based on trading volume.
- Default penalties: Interest rates jump to 15% upon an event of default.
- Multiple 8-K items: Filing covers items 1.01, 2.03, 3.02, 5.03, 7.01, and 9.01.
📋 Key Facts
- Total transaction value: $10,000,000 closed on June 3, 2026.
- Capital structure: 250 shares of Series A Preferred Stock ($2.5M), Secured Promissory Note A-1 ($2.72M), and Secured Promissory Note B ($5.0M).
- Collateral: $5,000,000 of the proceeds are held in a Cash Collateral Account; Notes are secured by substantially all assets except intellectual property.
- Interest rates: Note A-1 at 8% per annum; Note B at 5% per annum; both mature in 18 months.
- Preferred Stock: 8% annual return, non-convertible, with a stated value of $12,000 per share.
- Fees: Company paid a 7.0% placement agent fee on gross proceeds.
Imunon, Inc. reported its financial results for the first quarter ended March 31, 2026, and hosted a conference call to provide a business update.
📋 Key Facts
- The company issued a press release on May 12, 2026, regarding Q1 2026 financial results.
- A conference call and live internet broadcast were scheduled for May 12, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Financial results cover the quarter ended March 31, 2026.
Imunon, Inc. has entered into Change in Control (CIC) agreements with its top executive team, including the CEO, CMO, and General Counsel. These agreements provide for significant cash severance and full equity acceleration in the event of termination following a change in corporate control.
🚩 Red Flags
- Implementation of 'Golden Parachute' provisions for the entire C-suite simultaneously can indicate an impending sale or change in control.
- Significant cash outflows and equity dilution could occur upon a change in control, potentially impacting the net value to shareholders in an acquisition.
📋 Key Facts
- Agreements were entered into on May 1, 2026, with CEO Stacy Lindborg, CMO Douglas Faller, and GC Susan Eylward.
- CEO Stacy Lindborg is entitled to a lump sum payment of 2.5x the sum of her annual base salary and target bonus.
- Other executive officers (Faller and Eylward) are entitled to 1.5x their annual base salary and target bonus.
- The agreements include full acceleration of all outstanding equity awards and up to 24 months of health/life insurance premiums for the CEO (18 months for others).
- Benefits are triggered if the executive is terminated without cause or resigns for good reason within one year after or four months prior to a change in control.
Imunon, Inc. reported its financial results for the fiscal year ended December 31, 2025, and hosted a conference call to provide a business update. The filing serves as a routine disclosure of annual performance and management commentary.
📋 Key Facts
- Financial results reported for the fiscal year ended December 31, 2025.
- Press release issued and furnished as Exhibit 99.1 on March 31, 2026.
- Conference call and webcast held on March 31, 2026, at 11:00 AM ET.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
Imunon, Inc. has increased its At-the-Market (ATM) offering capacity by $7 million, bringing the total potential aggregate sales under its agreement with H.C. Wainwright & Co. to $17 million.
🚩 Red Flags
- Potential for shareholder dilution as the company expands its ability to sell shares directly into the market.
- Ongoing reliance on ATM offerings typically indicates a high cash burn rate and a lack of alternative financing for micro-cap companies.
📋 Key Facts
- Filed a prospectus supplement on March 23, 2026, to register an additional $7,000,000 in common stock.
- The total aggregate capacity of the ATM Sales Agreement is now $17,000,000, up from $10,000,000.
- As of the filing date, the company has already sold $4,797,848 of common stock under the existing agreement.
- H.C. Wainwright & Co., LLC is serving as the sales agent.
- The original Sales Agreement dates back to May 25, 2022, and was previously amended on May 15, 2024.